Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.
The report includes coverage of the following autoimmune diseases:
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse autoimmune collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Report scope
Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.
Autoimmune Collaboration and Licensing Deals includes:
Trends in autoimmune dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of autoimmune deal records covering pharmaceutical and biotechnology
The leading autoimmune deals by value
Most active autoimmune licensing dealmakers
In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:
Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune deals over the years
2.3. Autoimmune deals by deal type
2.4. Autoimmune deals by industry sector
2.5. Autoimmune deals by stage of development
2.6. Autoimmune deals by technology type
Chapter 3 - Financial deal terms for autoimmune deals
3.1. Introduction
3.2. Disclosed financials terms for autoimmune deals
3.3. Autoimmune deal headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune deal royalty rates
Chapter 4 - Leading autoimmune dealmakers and deals
